
## **Carolina Barnett**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/260996/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A cross-sectional study of gender differences in quality of life domains in patients with neurofibromatosis type 1. Orphanet Journal of Rare Diseases, 2022, 17, 40.	2.7	4
2	Characterizing the ASD–ADHD phenotype: measurement structure and invariance in a clinical sample. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2022, 63, 1534-1543.	5.2	13
3	Validating Automatic Diadochokinesis Analysis Methods Across Dysarthria Severity and Syllable Task in Amyotrophic Lateral Sclerosis. Journal of Speech, Language, and Hearing Research, 2022, 65, 940-953.	1.6	7
4	Protocol for psychometric evaluation of the Amyotrophic Lateral Sclerosis - Bulbar Dysfunction Index (ALS-BDI): a prospective longitudinal study. BMJ Open, 2022, 12, e060102.	1.9	2
5	Temporal Dispersion and Duration of the Distal Compound Muscle Action Potential Do Not Distinguish Diabetic Sensorimotor Polyneuropathy From Chronic Inflammatory Demyelinating Polyneuropathy. Frontiers in Neurology, 2022, 13, 872762.	2.4	1
6	An update on the use of immunoglobulins as treatment for myasthenia gravis. Expert Review of Clinical Immunology, 2022, 18, 703-715.	3.0	2
7	Retrospective study on the safety of <scp>COVID</scp> â€19 vaccination in myasthenia gravis. Muscle and Nerve, 2022, 66, 558-561.	2.2	10
8	Performance of different criteria for refractory myasthenia gravis. European Journal of Neurology, 2021, 28, 1375-1384.	3.3	9
9	Chronic immunoglobulin maintenance therapy in myasthenia gravis. European Journal of Neurology, 2021, 28, 639-646.	3.3	27
10	Myasthenia Gravis and Pregnancy: Toronto Specialty Center Experience. Canadian Journal of Neurological Sciences, 2021, , 1-5.	0.5	7
11	Validation of Articulatory Rate and Imprecision Judgments in Speech of Individuals With Amyotrophic Lateral Sclerosis. American Journal of Speech-Language Pathology, 2021, 30, 137-149.	1.8	7
12	Thymoma pathology and myasthenia gravis outcomes. Muscle and Nerve, 2021, 63, 868-873.	2.2	11
13	Telephone consultation for myasthenia gravis care during the COVID â€19 pandemic: Assessment of a novel virtual myasthenia gravis index. Muscle and Nerve, 2021, 63, 831-836.	2.2	9
14	Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher Disease. Neurology: Genetics, 2021, 7, e600.	1.9	3
15	Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials. Neurology, 2021, 97, S50-S63.	1.1	11
16	Fracture Risk in Patients with Myasthenia Gravis: A Population-Based Cohort Study. Journal of Neuromuscular Diseases, 2021, 8, 625-632.	2.6	2
17	People With Myasthenia Are Getting Better, But Are They Doing Well?. Neurology, 2021, , 10.1212/WNL.000000000012617.	1.1	1
18	Validation of the Italian version of the Myasthenia Gravis Impairment Index (MGII). Neurological Sciences, 2021. , 1.	1.9	0

#	Article	IF	CITATIONS
19	Preliminary Findings of a Dedicated Ocular Myasthenia Gravis Rating Scale: The OMGRate. Neuro-Ophthalmology, 2020, 44, 148-156.	1.0	9
20	Chronic stress, depression and personality type in patients with myasthenia gravis. European Journal of Neurology, 2020, 27, 204-209.	3.3	14
21	Patient-acceptable symptom states in myasthenia gravis. Neurology, 2020, 95, e1617-e1628.	1.1	33
22	Efficacy and safety of high infusion rate IVIG in CIDP. Muscle and Nerve, 2020, 62, 637-641.	2.2	2
23	Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. Neuro-Oncology Advances, 2020, 2, i141-i149.	0.7	18
24	Comparison of the single simple question and the patient acceptable symptom state in myasthenia gravis. European Journal of Neurology, 2020, 27, 2286-2291.	3.3	11
25	New insights into very-late-onset myasthenia gravis. Nature Reviews Neurology, 2020, 16, 299-300.	10.1	8
26	Prospective study of stress, depression and personality in myasthenia gravis relapses. BMC Neurology, 2020, 20, 261.	1.8	9
27	Novel Treatments in Myasthenia Gravis. Frontiers in Neurology, 2020, 11, 538.	2.4	54
28	Reliability and validity of speech & pause measures during passage reading in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 42-50.	1.7	26
29	Serious infections in patients with myasthenia gravis: populationâ€based cohort study. European Journal of Neurology, 2020, 27, 702-708.	3.3	23
30	Homonymous Retinal Ganglion Cell Layer Atrophy With Asymptomatic Optic Tract Glioma in Neurofibromatosis Type I. Frontiers in Neurology, 2020, 11, 256.	2.4	3
31	Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness. Journal of Neuromuscular Diseases, 2020, 7, 297-300.	2.6	8
32	Current pharmacotherapeutic options for myasthenia gravis. Expert Opinion on Pharmacotherapy, 2019, 20, 2295-2303.	1.8	20
33	Evidence of smallâ€fiber neuropathy in neurofibromatosis type 1. Muscle and Nerve, 2019, 60, 673-678.	2.2	9
34	Evidence of persistent improvements with longâ€ŧerm subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2019, 60, 643-644.	2.2	1
35	Qualitative, Patient-Centered Assessment of Muscle Cramp Impact and Severity. Canadian Journal of Neurological Sciences, 2019, 46, 735-741.	0.5	4
36	Clinical Measures of Bulbar Dysfunction in ALS. Frontiers in Neurology, 2019, 10, 106.	2.4	95

#	Article	IF	CITATIONS
37	Ultrasound in Multifocal Motor Neuropathy: Clinical and Electrophysiological Correlations. Journal of Clinical Neuromuscular Disease, 2019, 20, 165-172.	0.7	1
38	Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle and Nerve, 2019, 59, 404-410.	2.2	56
39	EQâ€5Dâ€5L and SFâ€6D health utility index scores in patients with myasthenia gravis. European Journal of Neurology, 2019, 26, 452-459.	3.3	12
40	Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations. Canadian Journal of Neurological Sciences, 2018, 45, 346-349.	0.5	3
41	Measuring Clinical Treatment Response in Myasthenia Gravis. Neurologic Clinics, 2018, 36, 339-353.	1.8	51
42	Sex differences in neuropathic pain intensity in diabetes. Journal of the Neurological Sciences, 2018, 388, 103-106.	0.6	38
43	Fatigue is a relevant outcome in patients with myasthenia gravis. Muscle and Nerve, 2018, 58, 197-203.	2.2	33
44	Nerve function varies with hemoglobin A1c in controls and type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 424-428.	2.3	5
45	High frequency of MGUS in DSP. Muscle and Nerve, 2018, 57, 1018-1021.	2.2	Ο
46	The utility of a single simple question in the evaluation of patients with myasthenia gravis. Muscle and Nerve, 2018, 57, 240-244.	2.2	27
47	Cramps frequency and severity are correlated with small and large nerve fiber measures in type 1 diabetes. Clinical Neurophysiology, 2018, 129, 122-126.	1.5	8
48	Toronto Clinical Neuropathy Score is valid for a wide spectrum of polyneuropathies. European Journal of Neurology, 2018, 25, 484-490.	3.3	23
49	The median to ulnar cross-sectional surface area ratio in carpal tunnel syndrome. Clinical Neurophysiology, 2018, 129, 2239-2244.	1.5	7
50	Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy. Neurology, 2018, 90, e2034-e2041.	1.1	6
51	Quantitative sonographic assessment of myotonia. Muscle and Nerve, 2018, 57, 146-149.	2.2	7
52	Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis. Muscle and Nerve, 2017, 55, 166-170.	2.2	27
53	Uric acid levels correlate with the severity of diabetic sensorimotor polyneuropathy. Journal of the Neurological Sciences, 2017, 379, 94-98.	0.6	12
54	Electrophysiological testing is correlated with myasthenia gravis severity. Muscle and Nerve, 2017, 56, 445-448.	2.2	19

#	Article	IF	CITATIONS
55	Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes. Journal of the Neurological Sciences, 2017, 372, 223-227.	0.6	13
56	Neurofibromatosis Clinic: A Report on Patient Demographics and Evaluation of the Clinic. Canadian Journal of Neurological Sciences, 2017, 44, 577-588.	0.5	5
57	Rituximab as treatment for anti-MuSK myasthenia gravis. Neurology, 2017, 89, 1069-1077.	1.1	185
58	Myasthenia Gravis Impairment Index. Neurology, 2017, 89, 2357-2364.	1.1	35
59	Recording Fewer Than 20 Potential Pairs With SFEMG May Suffice for the Diagnosis of Myasthenia Gravis. Journal of Clinical Neurophysiology, 2017, 34, 408-412.	1.7	5
60	International clinimetric evaluation of the MGâ€QOL15, resulting in slight revision and subsequent validation of the MGâ€QOL15r. Muscle and Nerve, 2016, 54, 1015-1022.	2.2	85
61	Repetitive facial nerve stimulation in myasthenia gravis 1min after muscle activation is inferior to testing a second muscle at rest. Clinical Neurophysiology, 2016, 127, 3294-3297.	1.5	6
62	Disease activity in chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences, 2016, 369, 204-209.	0.6	11
63	Development and validation of the Myasthenia Gravis Impairment Index. Neurology, 2016, 87, 879-886.	1.1	43
64	Frequent laboratory abnormalities in CIDP patients. Muscle and Nerve, 2016, 53, 862-865.	2.2	18
65	Construction and validation of the chronic acquired polyneuropathy patientâ€reported index (CAPâ€PRI): A diseaseâ€specific, healthâ€related qualityâ€ofâ€life instrument. Muscle and Nerve, 2016, 54, 9-17.	2.2	17
66	Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. Muscle and Nerve, 2016, 53, 872-876.	2.2	14
67	Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscular Disorders, 2016, 26, 41-46.	0.6	90
68	Laser Doppler Flare Imaging and Quantitative Thermal Thresholds Testing Performance in Small and Mixed Fiber Neuropathies. PLoS ONE, 2016, 11, e0165731.	2.5	33
69	Gelsolin Familial Amyloidosis Peripheral Neuropathy in Canada: A Case Report. Canadian Journal of Neurological Sciences, 2015, 42, 353-355.	0.5	5
70	Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale. Journal of Neuromuscular Diseases, 2015, 2, 301-311.	2.6	11
71	Elevated Vibration Perception Thresholds in CIDP Patients Indicate More Severe Neuropathy and Lower Treatment Response Rates. PLoS ONE, 2015, 10, e0139689.	2.5	8
72	Excessive Daytime Sleepiness in Patients with Myasthenia Gravis. Journal of Neuromuscular Diseases, 2015, 2, 93-97.	2.6	7

#	Article	IF	CITATIONS
73	Canadian Administrative Health Data Can Identify Patients with Myasthenia Gravis. Neuroepidemiology, 2015, 44, 108-113.	2.3	20
74	Effectiveness of Diagnostic Strategies in Suspected Delayed Cerebral Ischemia. Stroke, 2015, 46, 77-83.	2.0	4
75	Choosing drugs for the treatment of diabetic neuropathy. Expert Opinion on Pharmacotherapy, 2015, 16, 1805-1814.	1.8	6
76	Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination. PLoS ONE, 2015, 10, e0139674.	2.5	9
77	Chronic Inflammatory Demyelinating Polyneuropathy in Diabetes Patients. US Neurology, 2015, 11, 47.	0.2	2
78	Excessive Daytime Sleepiness in Patients with Myasthenia Gravis. Journal of Neuromuscular Diseases, 2015, 2, 93-97.	2.6	1
79	The Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes $\hat{a} \in$ An Observational Study. PLoS ONE, 2014, 9, e89344.	2.5	29
80	Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes. Expert Review of Clinical Immunology, 2014, 10, 1659-1665.	3.0	31
81	Prevalence of Muscle Cramps in Patients With Diabetes: Table 1. Diabetes Care, 2014, 37, e17-e18.	8.6	21
82	Thymectomy for non-thymomatous myasthenia gravis: a propensity score matched study. Orphanet Journal of Rare Diseases, 2014, 9, 214.	2.7	26
83	Incat disability score: A critical analysis of its measurement properties. Muscle and Nerve, 2014, 50, 164-169.	2.2	41
84	Minimal clinically important difference in myasthenia gravis: Outcomes from a randomized trial. Muscle and Nerve, 2014, 49, 661-665.	2.2	50
85	A Conceptual Framework for Evaluating Impairments in Myasthenia Gravis. PLoS ONE, 2014, 9, e98089.	2.5	23
86	Performance of individual items of the quantitative myasthenia gravis score. Neuromuscular Disorders, 2013, 23, 413-417.	0.6	18
87	Effects of napping on neuromuscular fatigue in myasthenia gravis. Muscle and Nerve, 2013, 48, 816-818.	2.2	12
88	Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 94-97.	1.9	28
89	Association of social support with quality of life in patients with polyneuropathy. Journal of the Peripheral Nervous System, 2013, 18, 37-43.	3.1	10
90	FcÎ <sup>3</sup> Receptor Polymorphisms Do Not Predict Response to Intravenous Immunoglobulin in Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 2012, 14, 1-6.	0.7	3

#	Article	IF	CITATIONS
91	The Quantitative Myasthenia Gravis Score. Journal of Clinical Neuromuscular Disease, 2012, 13, 201-205.	0.7	46
92	IVIG and PLEX in the treatment of myasthenia gravis. Annals of the New York Academy of Sciences, 2012, 1275, 1-6.	3.8	21
93	Predictors of response to immunomodulation in patients with myasthenia gravis. Muscle and Nerve, 2012, 45, 648-652.	2.2	18
94	Suralâ€ŧoâ€ŧadial amplitude ratio in the diagnosis of diabetic sensorimotor polyneuropathy. Muscle and Nerve, 2012, 45, 126-127.	2.2	15